Pros | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | - |
INDMoney rank | 5/8 | 1/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 12 Years | 12 Years | ||
Fund Size | 8352 Cr | 3689 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹500 Lumpsum ₹5000 | ||
Expense Ratio | 0.89% | 0.9% | ||
Exit Load | 1% | 0.5% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 40 | 32 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (12.57%) Divi's Laboratories Ltd (9.49%) Lupin Ltd (5.82%) Cipla Ltd (5.62%) Dr Reddy's Laboratories Ltd (5.49%) | Sun Pharmaceuticals Industries Ltd (12.73%) Divi's Laboratories Ltd (7.39%) Max Healthcare Institute Ltd Ordinary Shares (6.4%) Lonza Group Ltd ADR (4.81%) Cipla Ltd (4.77%) | ||
No of Sectors | 1 | 2 | ||
Top 3 Sectors | Health (100%) | Health (93.74%) Basic Materials (6.26%) | ||
Equity % | 98.58% | 96.08% | ||
Debt % | - | - | ||
P/E | 36.85 | 42.92 | ||
P/B | 5.96 | 6.01 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 2.76% | 2.44% | ||
3-Month Return | 7.71% | 4.46% | ||
6-Month Return | 0.03% | -0.33% | ||
1-Year Return | 18.05% | 21.91% | ||
3-Year Return | 26.73% | 30.17% | ||
5-Year Return | 23.19% | 25.18% |
Sharpe | 1.13 | 1.39 | ||
Alpha | 1.66 | 5.24 | ||
Beta | 0.9 | 0.84 | ||
Standard Deviation | 14.97 | 13.98 | ||
Information Ratio | 0.02 | 0.85 |
Description | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | SBI Healthcare Opportunities Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Sailesh Raj Bhan,Kinjal Desai | Tanmaya Desai |